The MedCity CONVERGE conference spotlighting innovation in cancer treatment June 19 in Philadelphia will highlight the role of healthcare startups in this space. Their approaches span digital pathology and drug delivery to improving the patient experience and state of the art testing.
Here’s a preview of the startups that will be presenting at the conference at the University City Science Center. Click here to register.
Cadex Genomics develops molecular diagnostic assays to improve cancer patient therapy. Its core technology detects retrotransposon elements found on all 23 chromosomes using venous blood and supports testing for most tumor types and therapies.
Cofactor Genomics is a predictive immune modeling company. With its molecular, informatic, and database tools, the company works with partners to support more expedient, cost-effective, and successful clinical trials.
Ezra’s technology seeks to enhance cancer detection, using AI to run MRI scans that are analyzed by radiologists to help screen for prostate cancer.
Medial EarlySign developed technology to detect early signs of high-risk patient trajectories in existing lab results and ordinary EHR data already collected in the course of routine care. The goal is to identify patients at high risk for certain conditions.
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Register now to be part of the conversation.
Proscia is a software company that is changing the way the world practices pathology to transform cancer research and diagnosis through its digital pathology platform and pipeline of AI algorithms.
Quench Medical is developing a novel aerosol drug delivery platform for more effective treatment of pulmonary airway diseases. The first application is an inhaled treatment for lung cancer.
Rx.Health is a spin-off from the Mount Sinai Health System. Its flagship product, RxUniverse, is the first enterprise-wide Digital Medicine delivery system that enables physicians to prescribe evidence-based mobile health applications, multi-media education, wearables, and therapeutics to patients at the point of care.
Savor Health is a knowledge-based personalized nutrition technology platform for people with cancer and other chronic medical conditions.
SEngine Precision Medicine developed a test that delivers treatment options of less toxic and more effective treatments for patient’s unique cancers.
XRHealth created an XR Platform that combines medical applications with advanced data analytics, providing a comprehensive solution for clinicians and patients.
Photo: Natalie Mis, Getty Images
